1. Abruzzese JL, Rosenberg A, Xiong Q, et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreative cancer. Proc Am Soc Clin Oncol 2001;20:Abstract 518.
2. Bartlett JM, Langdon SP, Simpson BJ, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996,73:301–6.
3. Beckmann MW, Niederacher D, Massenkeil G, et al. Expression analysis of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. Oncology 1996;53:441–7.
4. Bucci B, D’Agnano I, Botti C, et al. EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res 1997;17:769–74.
5. Chow NH, Liu HS, Lee EL, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997;17:1293–6.
6. Fischer-Colbrie J, Witt A, Heinzl H, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997;17:613–9.
7. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I–IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998;4:241–9.
8. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American joint committee on cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331–46.
9. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284–92.
10. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5 232 patients. Endocr Rev 1992;13:3–17.
11. Rieske P, Kordek R, Bartkowiak J, Debiec-Rychter M, et al. A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastoma. Pol J Pathol 1998;49:145–9.
12. Rusch V, Klimstra D, Venkatraman E, Pisters PW, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515–22.
13. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183–232.
14. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11-Refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001;20:Abstract 7.
15. Uegaki K, Nio Y, Inoue Y, et al. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 1997;17:3841–7.
16. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999;53:167–76.
17. Watanabe K, Tachibana O, Sata K, Yonekawa Y, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217–23.
18. Yoshida K, Hosoya Y, Sumi S, et al. Studies of the expression of epidermal growth factor receptor in human renal cell carcinoma: a comparison of immunohistochemical method versus ligand binding assay. Oncology 1997;54:220–5.
19. Leung TW, Cheung AN, Cheng DK, Wong LC, et al. Expression of c-erbB-2, epidermal growth factor receptor and pan-ras proto-oncogenes in adenocarcinoma of the cervix: correlation with clinical prognosis. Oncol Rep 2001;8:1159–64.
20. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Investig New Drugs 1999;17:259–69.
21. Chen WS, Lazar CS, Poenie M, Tsien RY, et al. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 1987;328:820–3.
22. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trail of indium 111-labelled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991;83:97–104.
23. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593–1611.
24. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958–70.
25. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in non human cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32S–40S.
26. Milas L, Mason K, Hunter N, Peterson S, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:323–5.
27. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909–16.
28. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6:4874–84.
29. Huang S-M, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell carcinomas of the head and the neck. Cancer Res 1999;59:1935–40.
30. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.
31. Raoul JL, Van Laethem JL, Mitry E, et al. Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid in patients with metastatic epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC). ECCO 2003, Abstract 289.
32. Tabernero JM, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. ASCO 2004, Abstract 3512.
33. Fisher GA, Kuo T, Cho CD, et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. ASCO 2004, Abstract 3514.
34. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin and vinorelbine vs. CV alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). ASCO 2004, Abstract 7012.
35. Kelly K, Hanna N, Rosenberg, A, et al. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell cancer. ASCO 2003:Abstract 2592.
36. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trail of gefinitib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237–46.
37. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefinitib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003;290:149–58.
38. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol 2004;22:777-84.
39. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol 2004;22:785-94.
40. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). ASCO 2004, Abstract 7010.
41. Herbst RS, Prager D, Hermann R, et al. TRIBUTE – A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). ASCO 2004, Abstract 7011
42. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20(Suppl 18):1–13.
43. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
Prof. Dr. Carsten Bokemeyer, Dr. Karin Oechsle, Priv.-Doz. Dr. Jörg T. Hartmann, Prof. Dr. Lothar Kanz, Abt. Innere Medizin II, Hämatologie/Onkologie/Immunologie/Rheumatologie, Universitätsklinik Tübingen, Otfried-Müller Str. 10, 72076 Tübingen, E-Mail: carsten.bokemeyer@